New oral anticoagulants in elderly patients

被引：61
作者：
Barco, Stefano [1 ,2 ]
Cheung, Yuk Wah [1 ]
Eikelboom, John W. [3 ,4 ]
Coppens, Michiel [1 ,3 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Internal Med, I-27100 Pavia, Italy
[3] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[4] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源：
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2013年 / 26卷 / 02期
关键词：
elderly; atrial fibrillation; stroke; venous thromboembolism; anticoagulants; dabigatran etexilate; rivaroxaban; apixaban; vitamin K antagonists; ATRIAL-FIBRILLATION; VENOUS THROMBOEMBOLISM; STROKE PREVENTION; RISK-FACTORS; WARFARIN; DABIGATRAN; APIXABAN; THERAPY; RIVAROXABAN; THROMBOPROPHYLAXIS;
D O I：
10.1016/j.beha.2013.07.011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The new oral anticoagulants (NOACs) dabigatran etexilate, rivaroxaban, and apixaban have been extensively studied for prevention and treatment of venous thromboembolic disease and for stroke prevention in atrial fibrillation. Elderly patients have the highest incidence of thrombotic complications but also have the highest risk of anticoagulant associated bleeding. In this review we critically examine the balance between risks and benefits of NOACs compared with vitamin K antagonists in elderly patients enrolled in phase 3 randomized controlled trials for the management of venous thrombosis and stroke prevention in atrial fibrillation. Results show that the favourable balance between risks and benefits of NOACs is preserved in the elderly population. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：215 / 224
页数：10
相关论文
共 41 条
  • [1] Apixaban for Extended Treatment of Venous Thromboembolism
    Agnelli, Giancarlo
    Buller, Harry R.
    Cohen, Alexander
    Curto, Madelyn
    Gallus, Alexander S.
    Johnson, Margot
    Porcari, Anthony
    Raskob, Gary E.
    Weitz, Jeffrey I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (08) : 699 - 708
  • [2] Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
    Alexander, John H.
    Lopes, Renato D.
    James, Stefan
    Kilaru, Rakhi
    He, Yaohua
    Mohan, Puneet
    Bhatt, Deepak L.
    Goodman, Shaun
    Verheugt, Freek W.
    Flather, Marcus
    Huber, Kurt
    Liaw, Danny
    Husted, Steen E.
    Lopez-Sendon, Jose
    De Caterina, Raffaele
    Jansky, Petr
    Darius, Harald
    Vinereanu, Dragos
    Cornel, Jan H.
    Cools, Frank
    Atar, Dan
    Luis Leiva-Pons, Jose
    Keltai, Matyas
    Ogawa, Hisao
    Pais, Prem
    Parkhomenko, Alexander
    Ruzyllo, Witold
    Diaz, Rafael
    White, Harvey
    Ruda, Mikhail
    Geraldes, Margarida
    Lawrence, Jack
    Harrington, Robert A.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08) : 699 - 708
  • [3] [Anonymous], PRAD EPAR PROD INF
  • [4] [Anonymous], 2012, STROKE
  • [5] [Anonymous], 2012, PROD MON EL
  • [6] Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
    Bauersachs, Rupert
    Berkowitz, Scott D.
    Brenner, Benjamin
    Buller, Harry R.
    Decousus, Herve
    Gallus, Alex S.
    Lensing, Anthonie W.
    Misselwitz, Frank
    Prins, Martin H.
    Raskob, Gary E.
    Segers, Annelise
    Verhamme, Peter
    Wells, Phil
    Agnelli, Giancarlo
    Bounameaux, Henri
    Cohen, Alexander
    Davidson, Bruce L.
    Piovella, Franco
    Schellong, Sebastian
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) : 2499 - 2510
  • [7] *BAY INC, 2012, XAR PROD MON
  • [8] Buller HR, 2012, ASH ANN M, V120, P20
  • [9] Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096
  • [10] Newly Identified Events in the RE-LY Trial
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Yusuf, Salim
    Reilly, Paul A.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) : 1875 - 1876
12345